Navigation Links
Savient Pharmaceuticals to Present at the Citi 2011 Global Healthcare Conference
Date:2/17/2011

EAST BRUNSWICK, N.J., Feb. 17, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that John H. Johnson, Chief Executive Officer of Savient will present at the Citi 2011 Global Healthcare Conference on Tuesday, March 1, 2011, at 4:00 p.m. Eastern Time.  The conference will be held at the New York Hilton in New York, NY.  

A live webcast of the presentation can be accessed through the investor relations section of the Company's website www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.

SVNT - G


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
2. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
3. Savient Submits Biologics License Application (BLA) for pegloticase
4. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
5. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
6. Savient Announces Appointment of David Gionco as Chief Financial Officer
7. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
8. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
9. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout
11. Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... Miami, FL on March 10, 2015 at 1:05 ... Financial Officer, will provide a corporate overview. The ... corporate website at www.halozyme.com , and a recording will ... access the live webcast, please log on to Halozyme,s website ...
(Date:3/3/2015)... 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... for odour control projects in North America , ... . "Bidding activity in 2015 continues to be ... a high volume year for bidding in 2014, we are pleased ... recent orders reflect the organization,s renewed focus on select market segments ...
(Date:3/3/2015)... /CNW/- SQI Diagnostics Inc. (TSX:V: SQD), a life sciences company ... for advanced microarray diagnostics, today announced it has ... Management team. In his capacity as CFO he ... a development stage to a commercially successful company ... capital market strategy and to secure funding to ...
(Date:3/3/2015)... Santa Clara, California (PRWEB) March 03, 2015 ... and development service company, has launched a new Life ... research reagents for preclinical research. , The first ... monoclonal antibody isotype controls, and soon to be released ... The company will continue to expand their life science ...
Breaking Biology Technology:Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Crown Bioscience Launches Life Science Product Catalog 2
... Inverness Medical,Innovations, Inc. (Amex: IMA ), a ... the consumer and professional markets, today,announced that Ron ... Finance, will attend the Jefferies 2nd Annual Healthcare,Conference ... presentation is,scheduled for Wednesday, June 25 at 3:15pm ...
... To Actively Pursue Acquisition Opportunities -, BRIDGEWATER, N.J. ... specialty pharmaceutical company, today announced,its launch backed by Warburg ... made an initial investment in GANIC from Warburg,Pincus Private ... in April., GANIC Pharmaceuticals was founded by a ...
... - Sale of Consumer Healthcare Business, - ... Science, Gerresheimer AG, the leading manufacturer of ... science industry, is selling its consumer healthcare,business. As ... which are not part of the core business ...
Cached Biology Technology:Inverness Medical Innovations to Present at Jefferies 2nd Annual Healthcare Conference held on June 25, 2008 2GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives 2GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives 3Gerresheimer Discontinues Marginal Operations 2
(Date:2/5/2015)... Jan. 28, 2015 Research and Markets ... of the "Global Biometrics Market (2014-2020): Market ... Countries " report to their offering. , ... Asia-Pacific is anticipated to overtake ... to increasing government spending towards IT security, government ...
(Date:1/22/2015)... 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry ... new website design. "When we launched FindBiometrics 12 ... Peter O,Neill , founder and CEO of FindBiometrics. "Now it,s ... from the key players on a very broad scale.  We ...
(Date:1/22/2015)... 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... on the recent success of the Wocket™ smart wallet at CES 2015 ... wallet was named as one of the "11 Hot Products at CES" ... Launched At CES So Far" by Newseveryday.com and "The top 10 gadgets ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... scientists have identified the behaviour of the mutant protein ... potential targets to treat the disease, a University of ... disease with no cure, characterized by a steady decline ... brain cells. The cause of the disease has long ...
... 2010) -- Earth,s climate is strongly influenced by the presence ... form of dust, ice and pollutants -- that find their ... There, water adsorbed on the surface of these particles can ... and snow. Researchers at Spain,s Centre d,Investigaci en ...
... chemical "nanoblasts" that punch tiny holes in the protective ... for getting therapeutic small molecules, proteins and DNA directly ... bursts of laser light trigger the tiny blasts, which ... admit therapeutic agents contained in the surrounding fluid. ...
Cached Biology News:Huntington's disease discovery provides new hope for treatment 2Artificially controlling water condensation leads to 'room-temperature ice' 2Nanoblasts from laser-activated nanoparticles move molecules, proteins and DNA into cells 2Nanoblasts from laser-activated nanoparticles move molecules, proteins and DNA into cells 3Nanoblasts from laser-activated nanoparticles move molecules, proteins and DNA into cells 4
... The iCycler thermal cycler with 96 x ... nucleic acid amplification (PCR) applications. It is ... (15-100 microliter samples) that is compatible with ... temperature monitoring and control by algorithm, block, ...
... compact benchtop and stackable multi-function incubator. ... a large display screen to accurately ... circulation inside to evenly distribute temperature ... easily calibrated from the microprocessor controller. ...
Tan solid. A glycoside used to permeabilize cellular membranes. Exhibits hemolytic activity. Contaminants: ash: ≤10%. Soluble in H 2 O. pH 4.4 - 4.6. RTECS VQ1400000, CAS 8047-15-2. References:...
...
Biology Products: